almagate has been researched along with Infectious Endophthalmitis in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (30.00) | 29.6817 |
2010's | 14 (70.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambresin, A; Becker, M; Casparis, H; Eich, G; Graf, N; Mantel, I; Michels, S; Wolfensberger, TJ | 1 |
Agrawal, S; Christoforidis, JB; Joshi, M | 1 |
Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Fortun, JA; Gregori, NZ; Kovach, JL; Moshfeghi, AA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE; Vaziri, K | 1 |
Becker, M; Brynskov, T; Freiberg, FJ; Michels, S; Munk, MR; Sørensen, TL; Wirth, MA; Wolf, S | 1 |
Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
Bakri, SJ; Diago, T; Edwards, AO; McCannel, CA; Pach, JM; Pulido, JS | 1 |
Castellarin, AA; Driscoll, S; Halperin, LS; Hassan, TS; Klein, KS; Prenner, JL; Roth, D; Walsh, MK | 1 |
Anderson, NG; Inman, ZD | 1 |
McCannel, CA | 1 |
Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA | 1 |
Inoue, M; Kadonosono, K; Kinoshita, S; Kobayakawa, S; Komori, H; Matsushima, H; Senoo, T; Sotozono, C; Suda, Y; Tanaka, K; Tochikubo, T | 1 |
Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Kovach, JL; Lalwani, GA; Lee, WH; Moshfeghi, AA; Murray, TG; Puliafito, CA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE | 1 |
Brown, DM; Chen, E; Cox, J; Lin, MY | 1 |
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF | 1 |
Fujita, K; Hattori, T; Mori, R; Nakashizuka, H; Shimada, H; Yuzawa, M | 1 |
Chen, TC; Englander, M; Kim, IK; Miller, JW; Paschalis, EI | 1 |
Meyer, CH | 1 |
Heimann, H; Meyer, CH; Ziemssen, F | 1 |
Cooney, M; Freund, KB; Klancnik, J; Kotsolis, A; Pilli, S; Slakter, J; Sorenson, J; Spaide, RF | 1 |
3 review(s) available for almagate and Infectious Endophthalmitis
Article | Year |
---|---|
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Humans; Infant, Newborn; Inflammation; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Risk; Vascular Endothelial Growth Factor A; Vitreous Body | 2013 |
Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Humans; Incidence; Intravitreal Injections; Ranibizumab; Vascular Endothelial Growth Factor A | 2011 |
[Intravitreal injection. Monitoring to avoid postoperative complications].
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract; Clinical Trials, Phase III as Topic; Endophthalmitis; Eye Hemorrhage; Female; Fetus; Hallucinations; Humans; Injections; Intraocular Pressure; Macular Degeneration; Mice; Paracentesis; Postoperative Complications; Pregnancy; Rabbits; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
17 other study(ies) available for almagate and Infectious Endophthalmitis
Article | Year |
---|---|
Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Female; Humans; Incidence; Intravitreal Injections; Operating Rooms; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Switzerland; Vascular Endothelial Growth Factor A | 2014 |
Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Florida; Humans; Incidence; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Diseases; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2015 |
LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Denmark; Endophthalmitis; Equipment Contamination; Eye Infections, Bacterial; Follow-Up Studies; Humans; Incidence; Intravitreal Injections; Operating Rooms; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Switzerland; Time Factors; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Ceftazidime; Drug Therapy, Combination; Endophthalmitis; Eye Infections; Female; Humans; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Staphylococcal Infections; Vancomycin; Vitreous Body | 2009 |
Endophthalmitis after anti-VEGF injections.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cohort Studies; Drug Therapy, Combination; Endophthalmitis; Humans; Injections; Macular Degeneration; Ranibizumab; Risk Factors; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
Topics: Anesthesia, Local; Anesthetics, Local; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Humans; Incidence; Intravitreal Injections; Lidocaine; Ranibizumab; Retrospective Studies; Time Factors; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage | 2011 |
Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Aqueous Humor; Bevacizumab; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Gram-Positive Bacterial Infections; Humans; Incidence; Intravitreal Injections; Japan; Middle Aged; Postoperative Complications; Ranibizumab; Retrospective Studies; Streptococcal Infections; Streptococcus oralis; Vascular Endothelial Growth Factor A; Vitreous Body | 2011 |
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Aqueous Humor; Bacteria; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Referral and Consultation; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2011 |
Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Glucocorticoids; Humans; Incidence; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Diseases; Retrospective Studies; Risk Factors; Streptococcal Infections; Triamcinolone Acetonide; Viridans Streptococci; Visual Acuity; Vitreous Body | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
[Intravitreal injections: AFSSAPS guide to good practice].
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical | 2012 |
Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctiva; Endophthalmitis; Eye Infections, Bacterial; Humans; Intravitreal Injections; Levofloxacin; Masks; Povidone-Iodine; Ranibizumab; Retrospective Studies; Therapeutic Irrigation; Vascular Endothelial Growth Factor A | 2013 |
Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Topics: Academic Medical Centers; Acute Disease; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Incidence; Intravitreal Injections; Male; Massachusetts; Postoperative Complications; Ranibizumab; Retinal Diseases; Retrospective Studies; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2013 |
[Introduction to the topic: anti-VEGF therapy in the management of AMD].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Endophthalmitis; Humans; Injections; Macular Degeneration; Postoperative Care; Ranibizumab; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Endophthalmitis; Eye Infections; Humans; Incidence; Injections; Male; Ranibizumab; Retrospective Studies; Risk Factors; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |